mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
Juan Andres Appointed to President, Strategic Partnerships and Enterprise Expansion
Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty unlawfully infringes patents Moderna filed between 2010 and 2016
Subscribe To Our Newsletter & Stay Updated
